High intensity care

OTHER2 trials

Sponsors

Heart Initiative, University Medical Center Ho Chi Minh City (UMC)

Conditions

Acute Heart Failure (AHF)Acute Heart Failure With Reduced Ejection FractionHeart Failure

Unknown Phase

Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP testinG, of Heart Failure Therapies

Heart InitiativeHeart Failure

Start: 2018-05-11End: 2021-10-31Target: 1800Updated: 2021-02-12

Vietnamese Rapid Acceleration Protocol for Intensifying Drug Therapy in Heart Failure With Reduced Ejection Fraction

RecruitingNCT06595290

University Medical Center Ho Chi Minh City (UMC)Acute Heart Failure (AHF), Acute Heart Failure With Reduced Ejection Fraction

Start: 2025-08-01End: 2029-01-01Target: 500Updated: 2025-08-05

Related Papers

Guideline-Directed Medical Therapy Use in the STRONG-HF Trial

Circulation Heart Failure2025-07-032 citations

Changes in Liver Function Tests, Congestion, and Prognosis After Acute Heart Failure: The STRONG-HF Trial.

2025-02-213 citations

Rapid Uptitration of Guideline-Directed Medical Therapies in Acute Heart Failure With and Without Atrial Fibrillation.

2024-08-144 citations

Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk.

2024-05-124 citations

Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial.

2024-05-121 citations

Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial

Circulation Heart Failure2024-03-0615 citations

Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial.

2024-02-0139 citations

Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction.

2023-06-0144 citations

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.

2022-11-07566 citations

Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP and GDF-15, of Heart Failure Therapies (STRONG-HF): Rationale and Design for a Multicentre, Randomized, Parallel-Group Study

European Journal of Heart Failure2019-08-1959 citations